ACELRX PHARMACEUT. DL-01 (R5XA) — Working Capital to Net Assets Ratio

ACELRX PHARMACEUT. DL-01 (R5XA) has a Working Capital to Net Assets ratio of 100.3% as of December 2025. Working capital of €17.09 Million (current assets of €20.90 Million minus current liabilities of €3.81 Million) is measured against net assets of €17.04 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See ACELRX PHARMACEUT. DL-01 net asset quality index to measure how much of total assets are equity-financed.